Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

导出 LinkOut

翻译打印收藏纠错

作者： Howard W,Bruckner ^[1] ; Sant P,Chawla ^[2] ; Nadezhda,Omelchenko ^[2] ; Don A,Brigham ^[3] ; Erlinda M,Gordon ^[4]

作者单位： Bruckner Oncology, New York, NY, United States. ^[1] Cancer Center of Southern California, Santa Monica, CA, United States. ^[2] Aveni Foundation, Santa Monica, CA, United States. ^[3] Cancer Center of Southern California, Santa Monica, CA, United States.;Aveni Foundation, Santa Monica, CA, United States. ^[4]

关键词 CCNG1 DeltaRex-G DeltaVax cancer gene therapy cell cycle control cyclin G1 inhibitor immunotherapy metastatic breast cancer

DOI 10.3389/fmmed.2023.1105680

PMID 39086675

发布时间 2024-08-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in molecular medicine

2023年3卷

1105680页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

Frontiers in molecular medicine

相似文献

Frontiers in molecular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

Frontiers in molecular medicine

相似文献

Frontiers in molecular medicine

相关期刊

检索历史清除